# Pfizer quarterly revenue

entity: /record/pfizer.md  
predicate: quarterly_revenue  
page: /record/pfizer/quarterly_revenue  
as_of: 2026-11-10  
cite: AsOf. "Pfizer quarterly revenue: 16,583,000,000 United States dollar", as of 2026-09-27. Claim clm_F01F5C40574B, https://asof.is/claim/clm_F01F5C40574B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.  

As of November 10, 2026, Pfizer's quarterly revenue on the AsOf record is $16.58 billion, dated September 27, 2026, from a primary source (sec.gov).

48 claims on Pfizer's quarterly revenue, 1 open and 47 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-10.

- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,583,000,000 United States dollar | valid 2026-09-27 to present | conf 0.95 | valid | [clm_F01F5C40574B](/claim/clm_F01F5C40574B.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,129,000,000 United States dollar | valid 2008-06-29 to 2008-09-28 | conf 0.95 | superseded | superseded_by [clm_2C0670CBF783](/claim/clm_2C0670CBF783.md) | [clm_99F313D7785B](/claim/clm_99F313D7785B.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 11,973,000,000 United States dollar | valid 2008-09-28 to 2009-03-29 | conf 0.95 | superseded | superseded_by [clm_94472D618440](/claim/clm_94472D618440.md) | [clm_2C0670CBF783](/claim/clm_2C0670CBF783.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 10,867,000,000 United States dollar | valid 2009-03-29 to 2009-06-28 | conf 0.95 | superseded | superseded_by [clm_879A3913E571](/claim/clm_879A3913E571.md) | [clm_94472D618440](/claim/clm_94472D618440.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 10,984,000,000 United States dollar | valid 2009-06-28 to 2009-09-27 | conf 0.95 | superseded | superseded_by [clm_53DFF240A651](/claim/clm_53DFF240A651.md) | [clm_879A3913E571](/claim/clm_879A3913E571.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 11,621,000,000 United States dollar | valid 2009-09-27 to 2010-04-04 | conf 0.95 | superseded | superseded_by [clm_AD86DB08CC3F](/claim/clm_AD86DB08CC3F.md) | [clm_53DFF240A651](/claim/clm_53DFF240A651.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,750,000,000 United States dollar | valid 2010-04-04 to 2010-07-04 | conf 0.95 | superseded | superseded_by [clm_8978D5AA8E4F](/claim/clm_8978D5AA8E4F.md) | [clm_AD86DB08CC3F](/claim/clm_AD86DB08CC3F.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 17,327,000,000 United States dollar | valid 2010-07-04 to 2010-10-03 | conf 0.95 | superseded | superseded_by [clm_ADF1E4CD8AB3](/claim/clm_ADF1E4CD8AB3.md) | [clm_8978D5AA8E4F](/claim/clm_8978D5AA8E4F.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,171,000,000 United States dollar | valid 2010-10-03 to 2011-04-03 | conf 0.95 | superseded | superseded_by [clm_483D9F5A030A](/claim/clm_483D9F5A030A.md) | [clm_ADF1E4CD8AB3](/claim/clm_ADF1E4CD8AB3.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,502,000,000 United States dollar | valid 2011-04-03 to 2011-07-03 | conf 0.95 | superseded | superseded_by [clm_A68C0CCB75B0](/claim/clm_A68C0CCB75B0.md) | [clm_483D9F5A030A](/claim/clm_483D9F5A030A.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,984,000,000 United States dollar | valid 2011-07-03 to 2011-10-02 | conf 0.95 | superseded | superseded_by [clm_DFEA39DE5FE8](/claim/clm_DFEA39DE5FE8.md) | [clm_A68C0CCB75B0](/claim/clm_A68C0CCB75B0.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 17,193,000,000 United States dollar | valid 2011-10-02 to 2012-04-01 | conf 0.95 | superseded | superseded_by [clm_9215DE851890](/claim/clm_9215DE851890.md) | [clm_DFEA39DE5FE8](/claim/clm_DFEA39DE5FE8.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 15,405,000,000 United States dollar | valid 2012-04-01 to 2012-07-01 | conf 0.95 | superseded | superseded_by [clm_96D458088120](/claim/clm_96D458088120.md) | [clm_9215DE851890](/claim/clm_9215DE851890.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 15,057,000,000 United States dollar | valid 2012-07-01 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_99B393C368BB](/claim/clm_99B393C368BB.md) | [clm_96D458088120](/claim/clm_96D458088120.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,976,000,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_CA56F63C64B0](/claim/clm_CA56F63C64B0.md) | [clm_99B393C368BB](/claim/clm_99B393C368BB.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,500,000,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_4B90345BB070](/claim/clm_4B90345BB070.md) | [clm_CA56F63C64B0](/claim/clm_CA56F63C64B0.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,973,000,000 United States dollar | valid 2013-06-30 to 2013-09-29 | conf 0.95 | superseded | superseded_by [clm_664E9DA37602](/claim/clm_664E9DA37602.md) | [clm_4B90345BB070](/claim/clm_4B90345BB070.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,643,000,000 United States dollar | valid 2013-09-29 to 2014-03-30 | conf 0.95 | superseded | superseded_by [clm_0B285A788601](/claim/clm_0B285A788601.md) | [clm_664E9DA37602](/claim/clm_664E9DA37602.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 11,353,000,000 United States dollar | valid 2014-03-30 to 2014-06-29 | conf 0.95 | superseded | superseded_by [clm_2F8C36CCD5B2](/claim/clm_2F8C36CCD5B2.md) | [clm_0B285A788601](/claim/clm_0B285A788601.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,773,000,000 United States dollar | valid 2014-06-29 to 2017-07-02 | conf 0.95 | superseded | superseded_by [clm_B6A35B59BF8C](/claim/clm_B6A35B59BF8C.md) | [clm_2F8C36CCD5B2](/claim/clm_2F8C36CCD5B2.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,896,000,000 United States dollar | valid 2017-07-02 to 2017-10-01 | conf 0.95 | superseded | superseded_by [clm_8058BCAD20C5](/claim/clm_8058BCAD20C5.md) | [clm_B6A35B59BF8C](/claim/clm_B6A35B59BF8C.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,168,000,000 United States dollar | valid 2017-10-01 to 2018-04-01 | conf 0.95 | superseded | superseded_by [clm_93302DB1670E](/claim/clm_93302DB1670E.md) | [clm_8058BCAD20C5](/claim/clm_8058BCAD20C5.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,906,000,000 United States dollar | valid 2018-04-01 to 2018-07-01 | conf 0.95 | superseded | superseded_by [clm_3C4862C01E8A](/claim/clm_3C4862C01E8A.md) | [clm_93302DB1670E](/claim/clm_93302DB1670E.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,466,000,000 United States dollar | valid 2018-07-01 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_FE067F51D4DB](/claim/clm_FE067F51D4DB.md) | [clm_3C4862C01E8A](/claim/clm_3C4862C01E8A.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,298,000,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_1E39DDDC01E7](/claim/clm_1E39DDDC01E7.md) | [clm_FE067F51D4DB](/claim/clm_FE067F51D4DB.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,118,000,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_CF98952D6203](/claim/clm_CF98952D6203.md) | [clm_1E39DDDC01E7](/claim/clm_1E39DDDC01E7.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,264,000,000 United States dollar | valid 2019-06-30 to 2019-09-29 | conf 0.95 | superseded | superseded_by [clm_889C767A67EA](/claim/clm_889C767A67EA.md) | [clm_CF98952D6203](/claim/clm_CF98952D6203.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,680,000,000 United States dollar | valid 2019-09-29 to 2020-03-29 | conf 0.95 | superseded | superseded_by [clm_78A6A26A31D2](/claim/clm_78A6A26A31D2.md) | [clm_889C767A67EA](/claim/clm_889C767A67EA.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,028,000,000 United States dollar | valid 2020-03-29 to 2020-06-28 | conf 0.95 | superseded | superseded_by [clm_B1CB42C2F7EF](/claim/clm_B1CB42C2F7EF.md) | [clm_78A6A26A31D2](/claim/clm_78A6A26A31D2.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 11,801,000,000 United States dollar | valid 2020-06-28 to 2020-09-27 | conf 0.95 | superseded | superseded_by [clm_C2761A47BD4C](/claim/clm_C2761A47BD4C.md) | [clm_B1CB42C2F7EF](/claim/clm_B1CB42C2F7EF.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,131,000,000 United States dollar | valid 2020-09-27 to 2021-04-04 | conf 0.95 | superseded | superseded_by [clm_4BE15DDF3498](/claim/clm_4BE15DDF3498.md) | [clm_C2761A47BD4C](/claim/clm_C2761A47BD4C.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 14,582,000,000 United States dollar | valid 2021-04-04 to 2021-07-04 | conf 0.95 | superseded | superseded_by [clm_A86BA19D0AEC](/claim/clm_A86BA19D0AEC.md) | [clm_4BE15DDF3498](/claim/clm_4BE15DDF3498.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 18,977,000,000 United States dollar | valid 2021-07-04 to 2021-10-03 | conf 0.95 | superseded | superseded_by [clm_2211869D267D](/claim/clm_2211869D267D.md) | [clm_A86BA19D0AEC](/claim/clm_A86BA19D0AEC.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 24,094,000,000 United States dollar | valid 2021-10-03 to 2022-04-03 | conf 0.95 | superseded | superseded_by [clm_7ED72F69640D](/claim/clm_7ED72F69640D.md) | [clm_2211869D267D](/claim/clm_2211869D267D.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 25,661,000,000 United States dollar | valid 2022-04-03 to 2022-07-03 | conf 0.95 | superseded | superseded_by [clm_2A546CD0F3BF](/claim/clm_2A546CD0F3BF.md) | [clm_7ED72F69640D](/claim/clm_7ED72F69640D.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 27,742,000,000 United States dollar | valid 2022-07-03 to 2022-10-02 | conf 0.95 | superseded | superseded_by [clm_016037710298](/claim/clm_016037710298.md) | [clm_2A546CD0F3BF](/claim/clm_2A546CD0F3BF.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 22,638,000,000 United States dollar | valid 2022-10-02 to 2023-04-02 | conf 0.95 | superseded | superseded_by [clm_639F87C977AC](/claim/clm_639F87C977AC.md) | [clm_016037710298](/claim/clm_016037710298.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 18,282,000,000 United States dollar | valid 2023-04-02 to 2023-07-02 | conf 0.95 | superseded | superseded_by [clm_2B41EF883A6E](/claim/clm_2B41EF883A6E.md) | [clm_639F87C977AC](/claim/clm_639F87C977AC.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 12,734,000,000 United States dollar | valid 2023-07-02 to 2023-10-01 | conf 0.95 | superseded | superseded_by [clm_32A8AAE2633D](/claim/clm_32A8AAE2633D.md) | [clm_2B41EF883A6E](/claim/clm_2B41EF883A6E.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,232,000,000 United States dollar | valid 2023-10-01 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_1956610004AC](/claim/clm_1956610004AC.md) | [clm_32A8AAE2633D](/claim/clm_32A8AAE2633D.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 14,879,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_D9138859F83D](/claim/clm_D9138859F83D.md) | [clm_1956610004AC](/claim/clm_1956610004AC.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,283,000,000 United States dollar | valid 2024-06-30 to 2024-09-29 | conf 0.95 | superseded | superseded_by [clm_4E14C8BB5BD2](/claim/clm_4E14C8BB5BD2.md) | [clm_D9138859F83D](/claim/clm_D9138859F83D.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 17,702,000,000 United States dollar | valid 2024-09-29 to 2025-03-30 | conf 0.95 | superseded | superseded_by [clm_3C91DD693306](/claim/clm_3C91DD693306.md) | [clm_4E14C8BB5BD2](/claim/clm_4E14C8BB5BD2.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 13,715,000,000 United States dollar | valid 2025-03-30 to 2025-06-29 | conf 0.95 | superseded | superseded_by [clm_502A97F831BF](/claim/clm_502A97F831BF.md) | [clm_3C91DD693306](/claim/clm_3C91DD693306.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 14,653,000,000 United States dollar | valid 2025-06-29 to 2025-09-28 | conf 0.95 | superseded | superseded_by [clm_259CE7C5C459](/claim/clm_259CE7C5C459.md) | [clm_502A97F831BF](/claim/clm_502A97F831BF.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,654,000,000 United States dollar | valid 2025-09-28 to 2026-03-29 | conf 0.95 | superseded | superseded_by [clm_04BC67D14071](/claim/clm_04BC67D14071.md) | [clm_259CE7C5C459](/claim/clm_259CE7C5C459.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 14,451,000,000 United States dollar | valid 2026-03-29 to 2026-06-28 | conf 0.95 | superseded | superseded_by [clm_565D11071768](/claim/clm_565D11071768.md) | [clm_04BC67D14071](/claim/clm_04BC67D14071.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 15,034,000,000 United States dollar | valid 2026-06-28 to 2026-09-27 | conf 0.95 | superseded | superseded_by [clm_F01F5C40574B](/claim/clm_F01F5C40574B.md) | [clm_565D11071768](/claim/clm_565D11071768.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm
- [Pfizer](/record/pfizer.md) | quarterly_revenue | 16,583,000,000 United States dollar | valid 2026-09-27 to present | conf 0.95 | valid | [clm_F01F5C40574B](/claim/clm_F01F5C40574B.md)
  sources: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm

## What replaced what

- $12.13 billion (2008-06-29 to 2008-09-28, [clm_99F313D7785B](/claim/clm_99F313D7785B.md)) was replaced by $11.97 billion from 2008-09-28 ([clm_2C0670CBF783](/claim/clm_2C0670CBF783.md))
- $11.97 billion (2008-09-28 to 2009-03-29, [clm_2C0670CBF783](/claim/clm_2C0670CBF783.md)) was replaced by $10.87 billion from 2009-03-29 ([clm_94472D618440](/claim/clm_94472D618440.md))
- $10.87 billion (2009-03-29 to 2009-06-28, [clm_94472D618440](/claim/clm_94472D618440.md)) was replaced by $10.98 billion from 2009-06-28 ([clm_879A3913E571](/claim/clm_879A3913E571.md))
- $10.98 billion (2009-06-28 to 2009-09-27, [clm_879A3913E571](/claim/clm_879A3913E571.md)) was replaced by $11.62 billion from 2009-09-27 ([clm_53DFF240A651](/claim/clm_53DFF240A651.md))
- $11.62 billion (2009-09-27 to 2010-04-04, [clm_53DFF240A651](/claim/clm_53DFF240A651.md)) was replaced by $16.75 billion from 2010-04-04 ([clm_AD86DB08CC3F](/claim/clm_AD86DB08CC3F.md))
- $16.75 billion (2010-04-04 to 2010-07-04, [clm_AD86DB08CC3F](/claim/clm_AD86DB08CC3F.md)) was replaced by $17.33 billion from 2010-07-04 ([clm_8978D5AA8E4F](/claim/clm_8978D5AA8E4F.md))
- $17.33 billion (2010-07-04 to 2010-10-03, [clm_8978D5AA8E4F](/claim/clm_8978D5AA8E4F.md)) was replaced by $16.17 billion from 2010-10-03 ([clm_ADF1E4CD8AB3](/claim/clm_ADF1E4CD8AB3.md))
- $16.17 billion (2010-10-03 to 2011-04-03, [clm_ADF1E4CD8AB3](/claim/clm_ADF1E4CD8AB3.md)) was replaced by $16.5 billion from 2011-04-03 ([clm_483D9F5A030A](/claim/clm_483D9F5A030A.md))
- $16.5 billion (2011-04-03 to 2011-07-03, [clm_483D9F5A030A](/claim/clm_483D9F5A030A.md)) was replaced by $16.98 billion from 2011-07-03 ([clm_A68C0CCB75B0](/claim/clm_A68C0CCB75B0.md))
- $16.98 billion (2011-07-03 to 2011-10-02, [clm_A68C0CCB75B0](/claim/clm_A68C0CCB75B0.md)) was replaced by $17.19 billion from 2011-10-02 ([clm_DFEA39DE5FE8](/claim/clm_DFEA39DE5FE8.md))
- $17.19 billion (2011-10-02 to 2012-04-01, [clm_DFEA39DE5FE8](/claim/clm_DFEA39DE5FE8.md)) was replaced by $15.41 billion from 2012-04-01 ([clm_9215DE851890](/claim/clm_9215DE851890.md))
- $15.41 billion (2012-04-01 to 2012-07-01, [clm_9215DE851890](/claim/clm_9215DE851890.md)) was replaced by $15.06 billion from 2012-07-01 ([clm_96D458088120](/claim/clm_96D458088120.md))
- $15.06 billion (2012-07-01 to 2012-09-30, [clm_96D458088120](/claim/clm_96D458088120.md)) was replaced by $13.98 billion from 2012-09-30 ([clm_99B393C368BB](/claim/clm_99B393C368BB.md))
- $13.98 billion (2012-09-30 to 2013-03-31, [clm_99B393C368BB](/claim/clm_99B393C368BB.md)) was replaced by $13.5 billion from 2013-03-31 ([clm_CA56F63C64B0](/claim/clm_CA56F63C64B0.md))
- $13.5 billion (2013-03-31 to 2013-06-30, [clm_CA56F63C64B0](/claim/clm_CA56F63C64B0.md)) was replaced by $12.97 billion from 2013-06-30 ([clm_4B90345BB070](/claim/clm_4B90345BB070.md))
- $12.97 billion (2013-06-30 to 2013-09-29, [clm_4B90345BB070](/claim/clm_4B90345BB070.md)) was replaced by $12.64 billion from 2013-09-29 ([clm_664E9DA37602](/claim/clm_664E9DA37602.md))
- $12.64 billion (2013-09-29 to 2014-03-30, [clm_664E9DA37602](/claim/clm_664E9DA37602.md)) was replaced by $11.35 billion from 2014-03-30 ([clm_0B285A788601](/claim/clm_0B285A788601.md))
- $11.35 billion (2014-03-30 to 2014-06-29, [clm_0B285A788601](/claim/clm_0B285A788601.md)) was replaced by $12.77 billion from 2014-06-29 ([clm_2F8C36CCD5B2](/claim/clm_2F8C36CCD5B2.md))
- $12.77 billion (2014-06-29 to 2017-07-02, [clm_2F8C36CCD5B2](/claim/clm_2F8C36CCD5B2.md)) was replaced by $12.9 billion from 2017-07-02 ([clm_B6A35B59BF8C](/claim/clm_B6A35B59BF8C.md))
- $12.9 billion (2017-07-02 to 2017-10-01, [clm_B6A35B59BF8C](/claim/clm_B6A35B59BF8C.md)) was replaced by $13.17 billion from 2017-10-01 ([clm_8058BCAD20C5](/claim/clm_8058BCAD20C5.md))
- $13.17 billion (2017-10-01 to 2018-04-01, [clm_8058BCAD20C5](/claim/clm_8058BCAD20C5.md)) was replaced by $12.91 billion from 2018-04-01 ([clm_93302DB1670E](/claim/clm_93302DB1670E.md))
- $12.91 billion (2018-04-01 to 2018-07-01, [clm_93302DB1670E](/claim/clm_93302DB1670E.md)) was replaced by $13.47 billion from 2018-07-01 ([clm_3C4862C01E8A](/claim/clm_3C4862C01E8A.md))
- $13.47 billion (2018-07-01 to 2018-09-30, [clm_3C4862C01E8A](/claim/clm_3C4862C01E8A.md)) was replaced by $13.3 billion from 2018-09-30 ([clm_FE067F51D4DB](/claim/clm_FE067F51D4DB.md))
- $13.3 billion (2018-09-30 to 2019-03-31, [clm_FE067F51D4DB](/claim/clm_FE067F51D4DB.md)) was replaced by $13.12 billion from 2019-03-31 ([clm_1E39DDDC01E7](/claim/clm_1E39DDDC01E7.md))
- $13.12 billion (2019-03-31 to 2019-06-30, [clm_1E39DDDC01E7](/claim/clm_1E39DDDC01E7.md)) was replaced by $13.26 billion from 2019-06-30 ([clm_CF98952D6203](/claim/clm_CF98952D6203.md))
- $13.26 billion (2019-06-30 to 2019-09-29, [clm_CF98952D6203](/claim/clm_CF98952D6203.md)) was replaced by $12.68 billion from 2019-09-29 ([clm_889C767A67EA](/claim/clm_889C767A67EA.md))
- $12.68 billion (2019-09-29 to 2020-03-29, [clm_889C767A67EA](/claim/clm_889C767A67EA.md)) was replaced by $12.03 billion from 2020-03-29 ([clm_78A6A26A31D2](/claim/clm_78A6A26A31D2.md))
- $12.03 billion (2020-03-29 to 2020-06-28, [clm_78A6A26A31D2](/claim/clm_78A6A26A31D2.md)) was replaced by $11.8 billion from 2020-06-28 ([clm_B1CB42C2F7EF](/claim/clm_B1CB42C2F7EF.md))
- $11.8 billion (2020-06-28 to 2020-09-27, [clm_B1CB42C2F7EF](/claim/clm_B1CB42C2F7EF.md)) was replaced by $12.13 billion from 2020-09-27 ([clm_C2761A47BD4C](/claim/clm_C2761A47BD4C.md))
- $12.13 billion (2020-09-27 to 2021-04-04, [clm_C2761A47BD4C](/claim/clm_C2761A47BD4C.md)) was replaced by $14.58 billion from 2021-04-04 ([clm_4BE15DDF3498](/claim/clm_4BE15DDF3498.md))
- $14.58 billion (2021-04-04 to 2021-07-04, [clm_4BE15DDF3498](/claim/clm_4BE15DDF3498.md)) was replaced by $18.98 billion from 2021-07-04 ([clm_A86BA19D0AEC](/claim/clm_A86BA19D0AEC.md))
- $18.98 billion (2021-07-04 to 2021-10-03, [clm_A86BA19D0AEC](/claim/clm_A86BA19D0AEC.md)) was replaced by $24.09 billion from 2021-10-03 ([clm_2211869D267D](/claim/clm_2211869D267D.md))
- $24.09 billion (2021-10-03 to 2022-04-03, [clm_2211869D267D](/claim/clm_2211869D267D.md)) was replaced by $25.66 billion from 2022-04-03 ([clm_7ED72F69640D](/claim/clm_7ED72F69640D.md))
- $25.66 billion (2022-04-03 to 2022-07-03, [clm_7ED72F69640D](/claim/clm_7ED72F69640D.md)) was replaced by $27.74 billion from 2022-07-03 ([clm_2A546CD0F3BF](/claim/clm_2A546CD0F3BF.md))
- $27.74 billion (2022-07-03 to 2022-10-02, [clm_2A546CD0F3BF](/claim/clm_2A546CD0F3BF.md)) was replaced by $22.64 billion from 2022-10-02 ([clm_016037710298](/claim/clm_016037710298.md))
- $22.64 billion (2022-10-02 to 2023-04-02, [clm_016037710298](/claim/clm_016037710298.md)) was replaced by $18.28 billion from 2023-04-02 ([clm_639F87C977AC](/claim/clm_639F87C977AC.md))
- $18.28 billion (2023-04-02 to 2023-07-02, [clm_639F87C977AC](/claim/clm_639F87C977AC.md)) was replaced by $12.73 billion from 2023-07-02 ([clm_2B41EF883A6E](/claim/clm_2B41EF883A6E.md))
- $12.73 billion (2023-07-02 to 2023-10-01, [clm_2B41EF883A6E](/claim/clm_2B41EF883A6E.md)) was replaced by $13.23 billion from 2023-10-01 ([clm_32A8AAE2633D](/claim/clm_32A8AAE2633D.md))
- $13.23 billion (2023-10-01 to 2024-03-31, [clm_32A8AAE2633D](/claim/clm_32A8AAE2633D.md)) was replaced by $14.88 billion from 2024-03-31 ([clm_1956610004AC](/claim/clm_1956610004AC.md))
- $14.88 billion (2024-03-31 to 2024-06-30, [clm_1956610004AC](/claim/clm_1956610004AC.md)) was replaced by $13.28 billion from 2024-06-30 ([clm_D9138859F83D](/claim/clm_D9138859F83D.md))
- $13.28 billion (2024-06-30 to 2024-09-29, [clm_D9138859F83D](/claim/clm_D9138859F83D.md)) was replaced by $17.7 billion from 2024-09-29 ([clm_4E14C8BB5BD2](/claim/clm_4E14C8BB5BD2.md))
- $17.7 billion (2024-09-29 to 2025-03-30, [clm_4E14C8BB5BD2](/claim/clm_4E14C8BB5BD2.md)) was replaced by $13.72 billion from 2025-03-30 ([clm_3C91DD693306](/claim/clm_3C91DD693306.md))
- $13.72 billion (2025-03-30 to 2025-06-29, [clm_3C91DD693306](/claim/clm_3C91DD693306.md)) was replaced by $14.65 billion from 2025-06-29 ([clm_502A97F831BF](/claim/clm_502A97F831BF.md))
- $14.65 billion (2025-06-29 to 2025-09-28, [clm_502A97F831BF](/claim/clm_502A97F831BF.md)) was replaced by $16.65 billion from 2025-09-28 ([clm_259CE7C5C459](/claim/clm_259CE7C5C459.md))
- $16.65 billion (2025-09-28 to 2026-03-29, [clm_259CE7C5C459](/claim/clm_259CE7C5C459.md)) was replaced by $14.45 billion from 2026-03-29 ([clm_04BC67D14071](/claim/clm_04BC67D14071.md))
- $14.45 billion (2026-03-29 to 2026-06-28, [clm_04BC67D14071](/claim/clm_04BC67D14071.md)) was replaced by $15.03 billion from 2026-06-28 ([clm_565D11071768](/claim/clm_565D11071768.md))
- $15.03 billion (2026-06-28 to 2026-09-27, [clm_565D11071768](/claim/clm_565D11071768.md)) was replaced by $16.58 billion from 2026-09-27 ([clm_F01F5C40574B](/claim/clm_F01F5C40574B.md))

## Questions this record answers

### What is Pfizer's current quarterly revenue?

$16.58 billion, dated September 27, 2026, from a primary source (sec.gov). The record asserts this claim as of November 10, 2026 (status valid, confidence 0.95).

### When did Pfizer's quarterly revenue last change?

The latest value on the record is $16.58 billion, dated September 27, 2026; before it the record holds $15.03 billion, dated June 28, 2026 and closed on September 27, 2026.

### What was Pfizer's quarterly revenue before $16.58 billion?

$15.03 billion, valid from June 28, 2026 to September 27, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/pfizer/quarterly_revenue (markdown: /record/pfizer/quarterly_revenue.md)
- Entity twin: /record/pfizer.md · timeline: /timelines/pfizer.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.